PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q1 2023. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,743,013 | +37.8% | 1,329,325 | 0.0% | 2.05% | +31.8% |
| Q2 2023 | $20,125,981 | +87.8% | 1,329,325 | 0.0% | 1.56% | +119.9% |
| Q1 2023 | $10,714,360 | -19.8% | 1,329,325 | +12.0% | 0.71% | -15.2% |
| Q4 2022 | $13,357,204 | +185.5% | 1,187,307 | +94.6% | 0.83% | +274.0% |
| Q3 2022 | $4,679,000 | -59.2% | 610,000 | +17.5% | 0.22% | -60.5% |
| Q2 2022 | $11,477,000 | +22.5% | 519,339 | +0.6% | 0.56% | +14.4% |
| Q1 2022 | $9,366,000 | +26.1% | 516,321 | 0.0% | 0.49% | +40.3% |
| Q4 2021 | $7,430,000 | +0.0% | 516,321 | +23.2% | 0.35% | -8.3% |
| Q3 2021 | $7,428,000 | +258.7% | 418,943 | +276.9% | 0.38% | +317.4% |
| Q2 2021 | $2,071,000 | +48.0% | 111,144 | +122.3% | 0.09% | +58.6% |
| Q1 2021 | $1,399,000 | – | 50,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |